These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 19180266

  • 1. Cdc7 as a potential new target for cancer therapy.
    Ito S, Taniyami C, Arai N, Masai H.
    Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
    [Abstract] [Full Text] [Related]

  • 2. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C.
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [Abstract] [Full Text] [Related]

  • 3. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A, Moll J, Colotta F.
    Clin Cancer Res; 2010 Sep 15; 16(18):4503-8. PubMed ID: 20647475
    [Abstract] [Full Text] [Related]

  • 4. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E.
    J Med Chem; 2009 Jan 22; 52(2):293-307. PubMed ID: 19115845
    [Abstract] [Full Text] [Related]

  • 5. Stopping replication, at the beginning.
    Jackson PK.
    Nat Chem Biol; 2008 Jun 22; 4(6):331-2. PubMed ID: 18488006
    [No Abstract] [Full Text] [Related]

  • 6. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, Cirla A, Cristiani C, D'Alessio R, Forte B, Isacchi A, Martina K, Menichincheri M, Molinari A, Montagnoli A, Orsini P, Pillan A, Roletto F, Scolaro A, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C.
    J Med Chem; 2008 Feb 14; 51(3):487-501. PubMed ID: 18201066
    [Abstract] [Full Text] [Related]

  • 7. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A, Bargiotti A, Brasca MG, Ciavolella A, Colombo N, Fachin G, Isacchi A, Menichincheri M, Molinari A, Montagnoli A, Pillan A, Rainoldi S, Sirtori FR, Sola F, Thieffine S, Tibolla M, Valsasina B, Volpi D, Santocanale C, Vanotti E.
    J Med Chem; 2009 Jul 23; 52(14):4380-90. PubMed ID: 19555113
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C, Tovar C, Yin X, Xu Q, Todorov IT, Vassilev LT, Chen L.
    Bioorg Med Chem Lett; 2009 Jan 15; 19(2):319-23. PubMed ID: 19071019
    [Abstract] [Full Text] [Related]

  • 9. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
    Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, Williams GH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2417-25. PubMed ID: 19318489
    [Abstract] [Full Text] [Related]

  • 10. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JT, Lee AY.
    EBioMedicine; 2018 Oct 01; 36():241-251. PubMed ID: 30293817
    [Abstract] [Full Text] [Related]

  • 11. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells.
    Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, Santocanale C.
    Cancer Res; 2004 Oct 01; 64(19):7110-6. PubMed ID: 15466207
    [Abstract] [Full Text] [Related]

  • 12. Cdc7 kinase - a new target for drug development.
    Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F.
    Eur J Cancer; 2010 Jan 01; 46(1):33-40. PubMed ID: 19815406
    [Abstract] [Full Text] [Related]

  • 13. Cdc7 kinase complex: a key regulator in the initiation of DNA replication.
    Masai H, Arai K.
    J Cell Physiol; 2002 Mar 01; 190(3):287-96. PubMed ID: 11857444
    [Abstract] [Full Text] [Related]

  • 14. Discovery of XL413, a potent and selective CDC7 inhibitor.
    Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC.
    Bioorg Med Chem Lett; 2012 Jun 01; 22(11):3727-31. PubMed ID: 22560567
    [Abstract] [Full Text] [Related]

  • 15. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 01; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 16. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.
    J Med Chem; 2010 Oct 28; 53(20):7296-315. PubMed ID: 20873740
    [Abstract] [Full Text] [Related]

  • 17. Drf1, a novel regulatory subunit for human Cdc7 kinase.
    Montagnoli A, Bosotti R, Villa F, Rialland M, Brotherton D, Mercurio C, Berthelsen J, Santocanale C.
    EMBO J; 2002 Jun 17; 21(12):3171-81. PubMed ID: 12065429
    [Abstract] [Full Text] [Related]

  • 18. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
    Irie T, Asami T, Sawa A, Uno Y, Hanada M, Taniyama C, Funakoshi Y, Masai H, Sawa M.
    Eur J Med Chem; 2017 Apr 21; 130():406-418. PubMed ID: 28279847
    [Abstract] [Full Text] [Related]

  • 19. Novel pyrrolopyridinone derivatives as anticancer inhibitors towards Cdc7: QSAR studies based on dockings by solvation score approach.
    Wu X, Zeng H, Zhu X, Ma Q, Hou Y, Wu X.
    Eur J Pharm Sci; 2013 Nov 20; 50(3-4):323-34. PubMed ID: 23933111
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
    Reichelt A, Bailis JM, Bartberger MD, Yao G, Shu H, Kaller MR, Allen JG, Weidner MF, Keegan KS, Dao JH.
    Eur J Med Chem; 2014 Jun 10; 80():364-82. PubMed ID: 24793884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.